Combined Small Cell Lung Carcinoma
Associated Genetic Biomarkers
NCI Definition: A morphologic variant of small cell lung carcinoma in combination with a non-small cell carcinoma. 
Combined small cell lung carcinomas most frequently harbor alterations in TP53, RB1, PTEN, EGFR, and TERT .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Exon 5 Mutation, and RB1 Mutation are the most common alterations in combined small cell lung carcinoma .
There is 1 clinical trial for combined small cell lung carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains combined small cell lung carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
EGFR is the most frequent gene inclusion criterion for combined small cell lung carcinoma clinical trials .
Carboplatin, durvalumab, and gemcitabine are the most common interventions in combined small cell lung carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.